pemetrexed / Generic mfg.  >>  Phase 3
Welcome,         Profile    Billing    Logout  

126 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pemetrexed / Generic mfg.
NCT05668988: A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

Recruiting
3
320
Europe, Canada, US, RoW
DZD9008, Pemetrexed+carboplatin
Dizal Pharmaceuticals
Non-small Cell Lung Cancer
02/26
10/27
APEX, NCT04762459: Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection

Enrolling by invitation
3
606
RoW
Almonertinib, Pemetrexed, Cisplatin
Chinese Academy of Medical Sciences, Jiangsu Hansoh Pharmaceutical Co., Ltd., GeneCast Biotechnology Co., Ltd.
Non-small Cell Lung Carcinoma
05/26
05/29
KEYLYNK-012, NCT04380636 / 2019-003237-41: Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/)

Calendar Jan 2026 - Dec 2026: Data from KEYLINK-012 trial in combination with Lynparza for stage III NSCLC
Active, not recruiting
3
870
Europe, Canada, Japan, US, RoW
Pembrolizumab, KEYTRUDA®, MK-3475, Olaparib, LYNPARZA®, MK-7339, AZD2281, KU-0059436, Placebo for olaparib, Etoposide, VEPESID®, Carboplatin, PARAPLATIN®, Cisplatin, PLATINOL®, Paclitaxel, TAXOL®, Pemetrexed, ALIMTA®, Thoracic Radiotherapy, Durvalumab, IMFINZI®
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
07/26
02/27
SUNRAY-01, NCT06119581: A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
eVOLVE-Meso, NCT06097728: MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Volrustomig, MEDI5752, Pemetrexed, Alimta, Carboplatin, Paraplatin, Cisplatin, Platinol, Nivolumab, Opdivo, Ipilimumab, Yervoy
AstraZeneca
Unresectable Pleural Mesothelioma
03/27
03/28
NCT05047250: A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer

Recruiting
3
60
RoW
Atezolizumab, Tecentriq
Hoffmann-La Roche
Non-Small Cell Lung Cancer
02/27
08/27
MK-2870-004, NCT06074588: Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations

Recruiting
3
556
Canada, US, RoW
Sacituzumab tirumotecan, SKB264, MK-2870, Docetaxel, TAXOTERE®, Pemetrexed, ALIMTA®
Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer (NSCLC)
05/27
03/30
AVANZAR, NCT05687266 / 2021-004606-21: Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations

Recruiting
3
1280
Europe, Canada, Japan, US, RoW
Datopotamab deruxtecan, Dato-DXd, Durvalumab, MEDI4736, Imfinzi, Carboplatin, Pembrolizumab, Cisplatin, Pemetrexed, Paclitaxel
AstraZeneca, AstraZeneca AB
NSCLC
02/27
02/27
TROPION-Lung07, NCT05555732: Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer

Recruiting
3
975
Europe, Canada, Japan, US, RoW
Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, Keytruda, Pemetrexed, Alimta, Pemfexy, Carboplatin, Cisplatin
Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC
Metastatic Non Small Cell Lung Cancer
08/27
08/27
STAR-121, NCT05502237: Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

Recruiting
3
720
Europe, Canada, Japan, US, RoW
Zimberelimab, GS-0122, AB122, Domvanalimab, GS-0154, AB154, Pembrolizumab, KEYTRUDA®, Carboplatin, Cisplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed
Gilead Sciences, Arcus Biosciences, Inc.
Non-small Cell Lung Cancer
09/27
09/27
AdvanTIG-306, NCT05791097: Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.

Withdrawn
3
980
NA
Ociperlimab, WCD118, Placebo, Tislelizumab, VDT482, Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel
Novartis Pharmaceuticals
Non-small Cell Lung Cancer (NSCLC)
12/27
12/27
M22-142, NCT06093503: Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein

Withdrawn
3
250
NA
Telisotuzumab Vedotin, ABBV-399, Osimertinib, Cisplatin, Carboplatin, Pemetrexed
AbbVie
Non-Small Cell Lung Cancer
04/28
04/28
eVOLVE-Lung02, NCT05984277: A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

Recruiting
3
900
Europe, Canada, Japan, US, RoW
Volrustomig, Pembrolizumab, Carboplatin, Paclitaxel, Pemetrexed
AstraZeneca
Metastatic Non-small Cell Lung Cancer
05/28
05/29
IMbrella B, NCT03768063 / 2018-003352-20: A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

Recruiting
3
1000
Europe, Canada, Japan, US, RoW
Atezolizumab, Tecentriq, Bevacizumab, Avastin, Alectinib, Alecensa, Cobimetinib, Cotellic, Vemurafenib, Zelboraf, FAP IL2V, simlukafusp alfa, Venetoclax, Venclexta, Enzalutamide, Xtandi, Pembrolizumab, Keytruda, Sunitinib, Sutent, Niraparib, Zejula, Cabozantinib, Cometriq, Pemetrexed, Paclitaxel, Emactuzumab, Rucaparib
Hoffmann-La Roche, F. Hoffmann-La Roche Ltd, F. Hoffmann- La Roche Ltd
Cancer
07/28
07/28
KEYVIBE-006, NCT05298423: Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/)

Recruiting
3
784
Europe, Japan, US, RoW
pembrolizumab/vibostolimab, MK-7684A, durvalumab, IMFINZI®, cisplatin, PLATINOL-AQ®, pemetrexed, ALIMTA®, etoposide, TOPOSAR®, carboplatin, PARAPLATIN®, paclitaxel, TAXOL®, thoracic radiotherapy
Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
09/28
09/29
DUBHE-L-304, NCT05487391: A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.

Not yet recruiting
3
632
NA
QL1706 injection, Vinorelbine Tartrate, Paclitaxel, Cisplatin, Carboplatin, Pemetrexed, Placebo
Qilu Pharmaceutical Co., Ltd.
Carcinoma, Non-Small-Cell Lung
10/28
10/31
TRITON, NCT06008093: A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients

Recruiting
3
280
US
Durvalumab, Tremelimumab, Pemetrexed, Background Platinum-based Chemotherapy, Pembrolizumab, Carboplatin, Cisplatin
AstraZeneca
Carcinoma, Non-Small-Cell Lung
08/27
03/31
NCT04750083: HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Recruiting
2/3
700
RoW
HX008, Pembrolizumab, pemetrexed, cisplatin/carboplatin
Taizhou Hanzhong biomedical co. LTD
Nonsquamous Non-small Cell Lung Cancer
09/22
09/23
NCT02784171 / 2016-002286-60: Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

Active, not recruiting
2/3
520
Europe, Canada
Cisplatin, Pemetrexed, Pembrolizumab
Canadian Cancer Trials Group, National Cancer Institute, Naples, Merck Sharp & Dohme LLC, Intergroupe Francophone de Cancerologie Thoracique
Mesothelioma
04/23
06/24
NCT06335355: A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients

Not yet recruiting
2/3
401
RoW
Adebrelimab + SHR-8068 + Pemetrexed + Carboplatin, Camrelizumab + Pemetrexed + Carboplatin, Adebrelimab + Pemetrexed + Carboplatin
Shanghai Shengdi Pharmaceutical Co., Ltd
Non-squamous Non-small Cell Lung Cancer
10/28
10/30
LIVIGNO-4, NCT06236438: Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Recruiting
2/3
840
Japan, US, RoW
Livmoniplimab, ABBV-151, Budigalimab, ABBV-181, Pembrolizumab, Pemetrexed, Cisplatin, Carboplatin
AbbVie
Non-Small Cell Lung Cancer
10/31
10/31
BFAST, NCT03178552 / 2017-000076-28: A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

Checkmark Results from B-FAST study for unresectable, advanced or metastatic NSCLC at ESMO 2021
Sep 2021 - Sep 2021: Results from B-FAST study for unresectable, advanced or metastatic NSCLC at ESMO 2021
Hourglass Apr 2021 - Jun 2021 : First-patient-in for cohort F of P2/3 B-FAST trial for NSCLC
Recruiting
2/3
1000
Europe, Canada, Japan, US, RoW
Alectinib, RO5424802, Atezolizumab, RO5541267, Pemetrexed, Cisplatin, Carboplatin, Gemcitabine, Entrectinib, RO7102122, Cobimetinib, RO5514041, Vemurafenib, RO5185426, Bevacizumab, RO4876646, GDC-6036, RO7435846, Docetaxel
Hoffmann-La Roche
Non-Small Cell Lung Cancer
08/28
08/28
NCT05756972: A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC

Recruiting
2/3
374
RoW
PM8002, Placebo, Carboplatin, Pemetrexed
Biotheus Inc.
NSCLC
03/25
12/25
SKYSCRAPER-06, NCT04619797 / 2020-002851-39: A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer

Calendar Jan 2025 - Dec 2025: Data from SKYSCRAPER-06 trial in combination with Tecentriq for advanced non squamous NSCLC
Active, not recruiting
2/3
542
Europe, Canada, Japan, US, RoW
Tiragolumab, MTIG7192A, Atezolizumab, Tecentriq, Pemetrexed, Carboplatin, Cisplatin, Tiragolumab Matching Placebo, Pembrolizumab
Hoffmann-La Roche
Non-small Cell Lung Cancer (NSCLC)
05/27
05/27
KRYSTAL-7, NCT04613596 / 2020-003101-58: Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation

Hourglass Jul 2023 - Dec 2023 : Data from KRYSTAL-7 trial in combination with pembrolizumab for advanced NSCLC
Checkmark Updated data from KRYSTAL-7 trial for advanced NSCLC at ESMO-IO 2022
Dec 2022 - Dec 2022: Updated data from KRYSTAL-7 trial for advanced NSCLC at ESMO-IO 2022
Recruiting
2/3
806
Europe, Canada, US, RoW
Adagrasib, Pembrolizumab, Pemrolizumab
Mirati Therapeutics Inc.
Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
10/28
10/29
NCT05800015: A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

Recruiting
2/3
950
Canada, US, RoW
fianlimab, REGN3767, cemiplimab, REGN2810, Libtayo, Pemetrexed, Alimta, Paclitaxel, Carboplatin, Paraplatin, Cisplatin, Platinol, Placebo
Regeneron Pharmaceuticals
Non-small Cell Lung Cancer
01/30
12/31
 

Download Options